[New strategy for the treatment of multiple myeloma].
Murakami
Hirokazu
H
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use; D015195:Drug Design; D004359:Drug Therapy, Combination; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000145:classification / Q000175:diagnosis / Q000628:therapy*; D010087:Oxides; D011379:Prognosis; D011480:Protease Inhibitors / Q000627:therapeutic use; D011687:Purines; D011719:Pyrazines / Q000627:therapeutic use; D000077546:Roscovitine; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D019172:Transplantation Conditioning
D020533:Angiogenesis Inhibitors; D001152:Arsenicals; D001897:Boronic Acids; D010087:Oxides; D011480:Protease Inhibitors; D011687:Purines; D011719:Pyrazines; D000077546:Roscovitine; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide; D000077237:Arsenic Trioxide